1145MO CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy
Yen, C.J., Chen, M-H., Chen, Y.Y., Bai, L-Y., Chen, J-S., Hsieh, J.C-H., Shih, Y-H., Wu, I-C., Chen, Y-L., Chen, C-M., Chao, T-Y., Chu, Y-W., Chien, D-S.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article